Clinical drug studies are an essential and central element of pharmaceutical research as they validate and ensure the efficacy and safety of a medication. Telekom has developed the documentation system TrialComplete Early Phase in collaboration with Boehringer Ingelheim for conducting Phase I studies, which will be used for the first time at the Human Pharmacological Center in Biberach an der Riss.
"We developed TrialComplete Early Phase together with Telekom to continue electronically capturing study data in the future,"says Dr. Dr. Nadine Beetz, head of the Human Pharmacological Center at Boehringer Ingelheim. "The solution will help us collectand process data quickly, effectively, and securely in our Phase I studies. Paper documentation is largely a thing of the past, andthe high availability of data in electronic form supports the safety of participants in our studies and accelerates the executionand evaluation of data. The feedback from our involved teams after the initial studies with TrialComplete Early Phase has been extremely positive."
Phase I studies, which also include first-in-human studies, are typically conducted on healthy volunteers. In this phase, thefundamental properties of a new drug, including its tolerability and safety, are thoroughly examined to determine its suitabilityfor human application.
